TSE:ONC Oncolytics Biotech (ONC) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free ONC Stock Alerts C$1.45 +0.07 (+5.07%) (As of 03/28/2024 ET) Add Compare Share Share Today's RangeC$1.39▼C$1.4550-Day RangeC$1.21▼C$1.7052-Week RangeC$1.20▼C$4.49Volume83,473 shsAverage Volume75,475 shsMarket CapitalizationC$109.36 millionP/E RatioN/ADividend Yield0.31%Price TargetC$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Get Oncolytics Biotech alerts: Email Address Oncolytics Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside520.7% UpsideC$9.00 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.44 out of 5 stars 3.5 Analyst's Opinion Consensus RatingOncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$9.00, Oncolytics Biotech has a forecasted upside of 520.7% from its current price of C$1.45.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ONC. Previous Next 0.0 Dividend Strength Dividend YieldOncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONC. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.14% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 6.98% of the stock of Oncolytics Biotech is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -3.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -3.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Oncolytics Biotech Stock (TSE:ONC)Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More ONC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONC Stock News HeadlinesMarch 16, 2024 | theglobeandmail.comClosing Bell: Oncolytics Bio down on Friday (ONC)March 11, 2024 | msn.comFutures Retreat SharplyMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 6, 2024 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANMarch 6, 2024 | finanznachrichten.deEcon Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth WinningMarch 6, 2024 | benzinga.comA Preview Of Oncolytics Biotech's EarningsMarch 2, 2024 | morningstar.comOncolytics Biotech Inc ONCFebruary 15, 2024 | markets.businessinsider.comReiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s PipelineMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.February 15, 2024 | finance.yahoo.comCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation TreatmentsFebruary 14, 2024 | theglobeandmail.comAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New TherapiesFebruary 7, 2024 | finanznachrichten.deUSA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024January 31, 2024 | finance.yahoo.comKaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic VirusesJanuary 6, 2024 | benzinga.comOncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, PredictionsDecember 14, 2023 | markets.businessinsider.comJonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON)December 7, 2023 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCSNovember 9, 2023 | finance.yahoo.comOncolytics Provides Update on Pancreatic Cancer Program for PelareorepNovember 3, 2023 | benzinga.comOncolytics Biotech's Earnings OutlookNovember 3, 2023 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2023 Financial Results and Operational HighlightsNovember 3, 2023 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITCNovember 3, 2023 | finance.yahoo.comOncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITCNovember 3, 2023 | msn.comOncolytics Biotech GAAP EPS of -$0.14 misses by $0.06November 3, 2023 | finance.yahoo.comOncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational HighlightsOctober 23, 2023 | marketwatch.comOncolytics Shares Rise 9.3% as Data Presented From Pancreatic Cancer StudyOctober 20, 2023 | finanznachrichten.deUSA News Group: Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment ResearchOctober 20, 2023 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational HighlightsSeptember 28, 2023 | ca.finance.yahoo.comStocks in play: Oncolytics Biotech, Inc.See More Headlines Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:ONC CUSIPN/A CIKN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price TargetC$9.00 High Stock Price TargetC$9.00 Low Stock Price TargetC$9.00 Potential Upside/Downside+520.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-27,750,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-102.66% Return on Assets-55.47% Debt Debt-to-Equity Ratio1.54 Current Ratio9.01 Quick Ratio8.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.34 per share Price / Cash Flow4.22 Book ValueC$0.37 per share Price / Book3.92Miscellaneous Outstanding Shares75,420,000Free FloatN/AMarket CapC$109.36 million OptionableNot Optionable Beta1.49 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Matthew C. Coffey M.B.A.Ph.D., President, CEO & DirectorMr. Kirk J. Look C.A.CA, Chief Financial OfficerDr. Thomas C. Heineman M.D.Ph.D., Chief Medical OfficerMs. Allison Hagerman P.Eng.P.M.P., Vice President of Product DevelopmentJon PattonDirector of Investor Relations & CommunicationMr. John Mark Lievonen F.C.A.FCA, LLD, ConsultantMore ExecutivesKey CompetitorsScythian BiosciencesCVE:SCYB138267 (COM.TO)TSE:COMMedicenna TherapeuticsTSE:MDNANovoheartCVE:NVHTheratechnologiesTSE:THView All Competitors ONC Stock Analysis - Frequently Asked Questions Should I buy or sell Oncolytics Biotech stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ONC shares. View ONC analyst ratings or view top-rated stocks. What is Oncolytics Biotech's stock price target for 2024? 2 equities research analysts have issued 12-month target prices for Oncolytics Biotech's stock. Their ONC share price targets range from C$9.00 to C$9.00. On average, they predict the company's share price to reach C$9.00 in the next twelve months. This suggests a possible upside of 520.7% from the stock's current price. View analysts price targets for ONC or view top-rated stocks among Wall Street analysts. How have ONC shares performed in 2024? Oncolytics Biotech's stock was trading at C$1.79 at the beginning of the year. Since then, ONC stock has decreased by 19.0% and is now trading at C$1.45. View the best growth stocks for 2024 here. When is Oncolytics Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our ONC earnings forecast. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR). How do I buy shares of Oncolytics Biotech? Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:ONC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.